• Je něco špatně v tomto záznamu ?

Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial

J. Jarosova, L. Zarivnijova, I. Cibulkova, J. Mares, P. Macinga, A. Hujova, P. Falt, O. Urban, J. Hajer, J. Spicak, T. Hucl

. 2023 ; 72 (12) : 2286-2293. [pub] 20231124

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000618
E-zdroje Online Plný text

NLK ProQuest Central od 1960-03-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 1960-03-01 do Před 6 měsíci

BACKGROUND: Endoluminal radiofrequency ablation (RFA) has been promoted as palliative treatment for patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC) in order to improve biliary drainage and eventually prolong survival. No high level evidence is, however, available on this technique. DESIGN: In this randomised controlled study, we compared endoluminal RFA plus stenting with stenting alone (control group) in patients with malignant biliary obstruction; metal stents were primarily placed. Primary outcome was overall survival; secondary outcomes were stent patency, quality of life and adverse events. In a superiority design, survival was assumed to be doubled by RFA as compared with 6.4 months in the control group (n=280). RESULTS: A total of 161 patients (male:female 90:71, mean age 71±9 years) were randomised before recruitment was terminated for futility after an interim analysis. Eighty-five patients had CCA (73 hilar, 12 distal) and 76 had pancreatic cancer. There was no difference in survival in both subgroups: for patients with CCA, median survival was 10.5 months (95% CI 6.7 to 18.3) in the RFA group vs 10.6 months (95% CI 9.0 to 24.8), p=0.58)) in the control group. In the subgroup with pancreatic cancer, median survival was 6.4 months (95% CI 4.3 to 9.7) for the RFA vs 7.7 months (95% CI 5.6 to 11.3), p=0.73) for the control group. No benefit was seen in the RFA group with regard to stent patency (at 12 months 40% vs 36% in CCA and 66% vs 65% in PDAC), and quality of life was unchanged by either treatment and comparable between the groups. Adverse events occurred in seven patients in each groups. CONCLUSION: A combination of endoluminal RFA and stenting was not superior to stenting alone in prolonging survival or improving stent patency in patients with malignant biliary obstruction. TRIAL REGISTRATION NUMBER: NCT03166436.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000618
003      
CZ-PrNML
005      
20240213093303.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/gutjnl-2023-329700 $2 doi
035    __
$a (PubMed)37652677
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jarosova, Jana $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Praha, Czech Republic $1 https://orcid.org/0000000300100637
245    10
$a Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial / $c J. Jarosova, L. Zarivnijova, I. Cibulkova, J. Mares, P. Macinga, A. Hujova, P. Falt, O. Urban, J. Hajer, J. Spicak, T. Hucl
520    9_
$a BACKGROUND: Endoluminal radiofrequency ablation (RFA) has been promoted as palliative treatment for patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC) in order to improve biliary drainage and eventually prolong survival. No high level evidence is, however, available on this technique. DESIGN: In this randomised controlled study, we compared endoluminal RFA plus stenting with stenting alone (control group) in patients with malignant biliary obstruction; metal stents were primarily placed. Primary outcome was overall survival; secondary outcomes were stent patency, quality of life and adverse events. In a superiority design, survival was assumed to be doubled by RFA as compared with 6.4 months in the control group (n=280). RESULTS: A total of 161 patients (male:female 90:71, mean age 71±9 years) were randomised before recruitment was terminated for futility after an interim analysis. Eighty-five patients had CCA (73 hilar, 12 distal) and 76 had pancreatic cancer. There was no difference in survival in both subgroups: for patients with CCA, median survival was 10.5 months (95% CI 6.7 to 18.3) in the RFA group vs 10.6 months (95% CI 9.0 to 24.8), p=0.58)) in the control group. In the subgroup with pancreatic cancer, median survival was 6.4 months (95% CI 4.3 to 9.7) for the RFA vs 7.7 months (95% CI 5.6 to 11.3), p=0.73) for the control group. No benefit was seen in the RFA group with regard to stent patency (at 12 months 40% vs 36% in CCA and 66% vs 65% in PDAC), and quality of life was unchanged by either treatment and comparable between the groups. Adverse events occurred in seven patients in each groups. CONCLUSION: A combination of endoluminal RFA and stenting was not superior to stenting alone in prolonging survival or improving stent patency in patients with malignant biliary obstruction. TRIAL REGISTRATION NUMBER: NCT03166436.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kvalita života $7 D011788
650    12
$a katetrizační ablace $x škodlivé účinky $x metody $7 D017115
650    12
$a radiofrekvenční ablace $7 D000078703
650    12
$a cholangiokarcinom $7 D018281
650    12
$a nádory slinivky břišní $x komplikace $x chirurgie $7 D010190
650    _2
$a stenty $x škodlivé účinky $7 D015607
650    12
$a cholestáza $x etiologie $x chirurgie $7 D002779
650    12
$a nádory žlučových cest $x komplikace $x chirurgie $7 D001650
650    _2
$a žlučové cesty intrahepatální $x chirurgie $7 D001653
650    _2
$a výsledek terapie $7 D016896
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zarivnijova, Lea $u Department of Internal Medicine II Gastroenterology and Geriatrics, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Cibulkova, Ivana $u Department of Internal Medicine, University Hospital Kralovske Vinohrady, Praha, Czech Republic
700    1_
$a Mares, Jan $u Department of Data Analysis, Statistics and Artificial Intelligence, Institute for Clinical and Experimental Medicine, Praha, Czech Republic
700    1_
$a Macinga, Peter $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Praha, Czech Republic
700    1_
$a Hujova, Alzbeta $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Praha, Czech Republic
700    1_
$a Falt, Premysl $u Department of Internal Medicine II Gastroenterology and Geriatrics, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Urban, Ondrej $u Department of Internal Medicine II Gastroenterology and Geriatrics, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Hajer, Jan $u Department of Internal Medicine, University Hospital Kralovske Vinohrady, Praha, Czech Republic
700    1_
$a Spicak, Julius $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Praha, Czech Republic
700    1_
$a Hucl, Tomas $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Praha, Czech Republic tomas.hucl@ikem.cz
773    0_
$w MED00009778 $t Gut $x 1468-3288 $g Roč. 72, č. 12 (2023), s. 2286-2293
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37652677 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093300 $b ABA008
999    __
$a ok $b bmc $g 2049333 $s 1210312
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 72 $c 12 $d 2286-2293 $e 20231124 $i 1468-3288 $m Gut $n Gut $x MED00009778
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...